+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Global Cancer Pain Market, By Drug Type, By Disease Indication, Estimation & Forecast, 2017 - 2030

  • ID: 5547468
  • Report
  • January 2022
  • Region: Global
  • 278 Pages
  • Astute Analytica
UP TO OFF until Jul 31st 2022

FEATURED COMPANIES

  • Daiichi Sankyo Co., Ltd.
  • Orexo AB
  • Pfizer Inc.
  • Roche Holding AG
The global cancer pain market accounted for a market size of USD 6,716.2 Million in 2021 and is projected to reach USD 9,951.2 Million by 2030, at a growth rate of 4.6% during the forecast period.



The global cancer pain market is expected to grow owing to various factors such as the niche penetration of healthcare facilities for cancer diagnostics coupled with the rising healthcare expenditure & government support worldwide. Furthermore, growing prevalence of cancer pain is also estimated to boost the market growth. According to the National Cancer Institute, as of December 2021, around 20-50% cancer patients suffer from pain. Also, according to the Centers for Disease Control and Prevention (CDC), roughly 15.5 million cancer survivors (those who have had a cancer diagnosis) were alive in the United States in 2016, with that figure predicted to rise to over 20 million by 2026. Despite the driving factors, accessibility to facilities and high cost of treatment are expected to hinder the market growth during the forecast period.

Growth Influencers:


Rising healthcare expenditure and government support worldwide

With the growing prevalence of cancer, the awareness for the disease as well as the associated pain is also increasing. This is also leading to the rising healthcare expenditure for diagnosis and treatment of the cancer associated pain. According to the OECD, the preliminary estimates of healthcare spending for a group of 16 OECD countries jumped to about 9.9% of GDP in 2020. Therefore, the rising healthcare expenditure and government support worldwide is anticipated to fuel the market growth.

Segments Overview:


The global cancer pain market is segmented the drug type and disease indication.

By Drug Type,

  • Opioids/ Narcotics
  • Hydromorphone (Dilaudid)
  • Morphine (Kadian, M-Eslon Others)
  • Codeine
  • Oxycodone
  • Tramadol
  • Fentanyl
  • Others
  • Non-Opioids
  • Acetaminophen
  • Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
  • Nerve Blocks

The opioids/narcotics segment is estimated to account for the largest market share of approximately 75% owing to the growing prevalence of cancer pain and the growing product pipeline. Within this segment, the codeine sub-segment is expected to witness the highest CAGR of 5.5%. This is because codeine is required in less amount as compared to the other opioids. In addition, the non-opioids segment is estimated to account for a market opportunity of around USD 482.7 million during 2022 to 2030. Within this segment, the non-steroidal anti-inflammatory drugs (NSAIDS) segment is estimated to surpass a market size of USD 1,000 million by 2022. This is because of the low cost as well as easy availability of these drugs.

By Disease Indication,

  • Lung Cancer
  • Colorectal Cancer
  • Breast Cancer
  • Prostate Cancer
  • Blood Cancer
  • Others

The breast cancer segment is expected to witness the fastest growth rate of 5.5% during the forecast period and is also estimated to account for the largest market share of around 16% in 2021, owing to the increasing prevalence of breast cancer. According to the World Health Organization (WHO), there were around 2.3 million women diagnosed with breast cancer in 2020. As per the same source, about 685,000 deaths occurred globally in 2020, due to breast cancer. On the other hand, the colorectal cancer segment accounted for the lowest revenue of USD 549.5 million by 2030.

Regional Overview


Based on region, the global Cancer pain market is divided into Europe, North America, Asia Pacific, South America, and the Middle East & Africa.

The North America region is expected to hold the largest market share of around 42% in 2021. This amounted to a market size of USD 2,834.8 million. This is owing to the growing incidence rate of cancer and presence of various market players in the region. In the U.S. around 1,194 people below the age of 20 years were suffering from cancer pain in 2021. Total number of people suffering from cancer pain in 2021 in the country was 1,16,182. Also, this number was expected to reach 1,743 people below the age of 20 and 1,59,889 total population suffering from cancer pain by 2030.

Asia Pacific region witnessed the fastest growth rate of 5.7% during the forecast period owing to the easy availability of pain therapeutics, growing geriatric population, and rising awareness of cancer.

Competitive Landscape


Key players operating in the global cancer pain market include Orexo AB, MundiPharma International Ltd., Biodelivery Sciences International Inc., Hisamitsu Pharma Co., Teva Pharma Industries Ltd., CK life Science (WEX Pharma), Daiichi Sankyo Co., Pfizer Inc., Roche Holding AG, and Other Prominent Players. The cumulative market share of 4 major players is near about 35%.

These market players are involved in collaborations, mergers & acquisitions, and new product launches to strengthen their market presence. For instance, in December 2021, Pfizer collaborated with Amazon Web Services, Inc. (AWS) for creating cloud-based solutions for improving the development, manufacturing, and distribution of medicines for clinical trials testing. The company enhanced the company’s position in the market.

Marketed and Emerging Drugs

There are many marketed drugs in the market by various companies. For instance, ULTRAM (tramadol hydrochloride) by Janssen Ortho, LLC; Hydromorphone Hydrochrloride by Janssen Korea, Ltd, Oxycodone by Taiwan Mundipharma Pharmaceuticals Ltd, and Lazanda (Fentanyl) by Insys Therapeutics, Inc., among others.

Many market players are also investing in various research and development activities for development of more effective drugs for the treatment of cancer pain. Some of the emerging drugs include Morphine sulfate by Tetra Biopharma/Cognitive Research Corporatio, Resiniferatoxin by Sorrento Therapeutics, Inc., and Pregabalin by Institut Cancerologie de l'Ouest/Grünenthal GmbH. Sorrento’s resiniferatoxin received FDA clearance for proceeding with its Phase 2 clinical study for using epidural resiniferatoxin for treatment of intractable pain associated with advanced cancer.

The global Cancer pain market report provides insights on the below pointers:

  • Market Penetration: Provides comprehensive information on the market offered by the prominent players
  • Market Development: The report offers detailed information about lucrative emerging markets and analyzes penetration across mature segments of the markets
  • Market Diversification: Provides in-depth information about untapped geographies, recent developments, and investments
  • Competitive Landscape Assessment: Mergers & acquisitions, certifications, product launches in the global cancer pain market have been provided in this research report. In addition, the report also emphasizes the SWOT analysis of the leading players.
  • Product Development & Innovation: The report provides intelligent insights on future technologies, R&D activities, and breakthrough product developments
  • Cancer Market Growth Forecast (USD Million), 2017-2030
  • Epidemiology & Patient Population; 8MM Incident Patient Population of Cancer Pain
  • Country Wise Epidemiology of Cancer Pain: U.S., EU5 (Germany, France, Italy, Spain, and the UK), Japan, China, and India
  • Treatment & Management of Cancer Pain: Treatment Guidelines, WHO Guidelines for Cancer Pain Management. ESMO Guidelines for Cancer Pain Management
  • Marketed Drugs: ULTRAM (Tramadol Hydrochloride)-Janssen Ortho, LLC - Product Description, Other Development Activities, Clinical Development, Clinical Trials Information, Safety & Efficacy, Product Profile; Hydromorphone Hydrochloride (HCl)-Janssen Korea, Ltd; Oxycodone-Taiwan Mundipharma Pharmaceuticals Ltd; Lazanda (Fentanyl)-Insys Therapeutics, Inc.
  • Emerging Drugs: Morphine Sulfate-Tetra Biopharma/Cognitive Research Corporation-Product Description, Regulatory Milestones, Clinical Development, Ongoing Current Pipeline Activity, Safety & Efficacy, product Profile; Resiniferatoxin-Sorrento Therapeutics, Inc.; Pregabalin-Institut Cancerologie de I’Quest/Grunenthal GmbH

The global Cancer pain market report answers questions such as:

  • What is the market size and forecast of the Global Cancer pain Market?
  • What are the inhibiting factors and impact of COVID-19 on the Global Cancer pain Market during the assessment period?
  • Which are the products/segments/applications/areas to invest in over the assessment period in the Global Cancer pain Market?
  • What is the competitive strategic window for opportunities in the Global Cancer pain Market?
  • What are the technology trends and regulatory frameworks in the Global Cancer pain Market?
  • What is the market share of the leading players in the Global Cancer pain Market?
  • What modes and strategic moves are considered favorable for entering the Global Cancer pain Market?
Frequently Asked Questions about the Global Cancer Pain Market

What is the estimated value of the Global Cancer Pain Market?

The Global Cancer Pain Market was estimated to be valued at $6716.2 Million in 2021.

What is the growth rate of the Global Cancer Pain Market?

The growth rate of the Global Cancer Pain Market is 4.5%, with an estimated value of $9951.2 Million by 2030.

What is the forecasted size of the Global Cancer Pain Market?

The Global Cancer Pain Market is estimated to be worth $9951.2 Million by 2030.

Who are the key companies in the Global Cancer Pain Market?

Key companies in the Global Cancer Pain Market include Aoxing Pharmaceutical Company, Inc., BioDelivery Sciences International, Inc., CK Life Sciences (WEX Pharmaceuticals), Daiichi Sankyo Co., Ltd., Hisamitsu Pharmaceutical Co., Inc., Mundipharma International Limited, Orexo AB, Pfizer Inc. and Roche Holding AG.
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Daiichi Sankyo Co., Ltd.
  • Orexo AB
  • Pfizer Inc.
  • Roche Holding AG

Chapter 1. Research Framework
1.1. Objective
1.2. Product Overview
1.2.1. Market Segmentation
1.2.2. Market & Segment Definitions
1.3. Research Methodology
1.3.1. Supply Side (Revenue Analysis)
1.3.2. Demand Side (Spending Analysis)
1.3.3. Data Heads Tracked
1.3.3.1. Quantitative Research
1.3.3.2. Qualitative Research
1.3.4. List of Primary & Secondary Sources
1.3.4.1. Sample Size
1.3.4.2. Sample Distribution
1.3.5. Market Size Estimation
1.3.5.1. Assumption for the Study
1.3.5.2. Data Triangulation
Chapter 2. Executive Summary: Global Cancer Pain Market
Chapter 3. Introduction
3.1. Cancer Market Growth Forecast (US$ Mn), 2017 - 2030
3.2. PEST (Political, Economic, Social, Technological) Analysis
Chapter 4. Global Cancer Pain Market Overview
4.1. Industry Value Chain Analysis
4.1.1. Material Provider
4.1.2. Manufacturers
4.1.3. Distributor
4.1.4. End Users
4.2. Porter's Five Forces Analysis
4.2.1. Bargaining Power of Suppliers
4.2.2. Bargaining Power of Buyers
4.2.3. Threat of Substitutes
4.2.4. Threat of New Entrants
4.2.5. Degree of Competition
4.3. Market Dynamics
4.3.1. Key Trends
4.3.2. Growth Drivers
4.3.3. Challenges/ Restraints
4.4. Market Opportunity Assessment
4.4.1. Activity Mapping of Top Players (Ansoff's Matrix)
4.5. Market Growth and Outlook
4.5.1. Market Growth Forecast (US$ Mn), 2017-2030
4.5.1.1. ASTUTE Analysis
4.5.1.2. Optimistic Outlook
4.5.1.3. Reserved Outlook
4.6. Covid-19 Impact Assessment on Market Growth Trend
4.6.1. Growth Trend Shift Analysis
4.6.2. Industry Best Practices
4.7. Epidemiology and Patient Population
4.7.1. Key Findings
4.7.2. Epidem and Market Methodology
4.7.3. 8MM Incident Patient Population of Cancer Pain
4.8. Country Wise-Epidemiology of Cancer Pain
4.8.1. United States Epidemiology
4.8.1.1. Assumptions and Rationale
4.8.1.2. Total Incident Cases of Cancer Pain in the United States
4.8.1.3. Age-Specific Incidence of Cancer Pain in United States
4.8.2. EU5 Epidemiology
4.8.2.1. Germany
4.8.2.1.1. Assumptions and Rationale
4.8.2.1.2. Total Incident Cases of Cancer Pain in the Germany
4.8.2.1.3. Age-Specific Incidence of Cancer Pain in Germany
4.8.2.2. France
4.8.2.2.1. Assumptions and Rationale
4.8.2.2.2. Total Incident Cases of Cancer Pain in the France
4.8.2.2.3. Age-Specific Incidence of Cancer Pain in France
4.8.2.3. Italy
4.8.2.3.1. Assumptions and Rationale
4.8.2.3.2. Total Incident Cases of Cancer Pain in the Italy
4.8.2.3.3. Age-Specific Incidence of Cancer Pain in Italy
4.8.2.4. Spain
4.8.2.4.1. Assumptions and Rationale
4.8.2.4.2. Total Incident Cases of Cancer Pain in the Spain
4.8.2.4.3. Age-Specific Incidence of Cancer Pain in Spain
4.8.2.5. UK
4.8.2.5.1. Assumptions and Rationale
4.8.2.5.2. Total Incident Cases of Cancer Pain in UK
4.8.2.5.3. Age-Specific Incidence of Cancer Pain in UK
4.8.3. Japan Epidemiology
4.8.3.1. Assumptions and Rationale
4.8.3.2. Total Incident Cases of Cancer Pain in Japan
4.8.3.3. Age-Specific Incidence of Cancer Pain in Japan
4.8.4. China Epidemiology
4.8.4.1. Assumptions and Rationale
4.8.4.2. Total Incident Cases of Cancer Pain in China
4.8.4.3. Age-Specific Incidence of Cancer Pain in China
4.8.5. India Epidemiology
4.8.5.1. Assumptions and Rationale
4.8.5.2. Total Incident Cases of Cancer Pain in India
4.8.5.3. Age-Specific Incidence of Cancer Pain in India
4.8.6. Treatment and Management of Cancer Pain
4.8.6.1. Treatment Guidelines
4.8.6.2. WHO guidelines for Cancer Pain Management
4.8.6.3. ESMO guidelines for Cancer Pain Management
4.8.7. Unmet Needs
4.8.8. Marketed Drugs
4.8.8.1. ULTRAM® (tramadol hydrochloride): Janssen Ortho, LLC
4.8.8.1.1. Product Description
4.8.8.1.2. Regulatory Milestones
4.8.8.1.3. Clinical Development
4.8.8.1.4. Ongoing Current Pipeline Activity
4.8.8.1.5. Safety and efficacy
4.8.8.1.6. Product Profile
4.8.8.2. Hydromorphone Hydrochloride (HCI): Janssen Korea, Ltd.
4.8.8.3. Oxycodone: Taiwan Mundipharma Pharmaceuticals Ltd.
4.8.8.4. Lazanda (Fentanyl):Insys Therapeutics, Inc.
4.8.9. Emerging Drugs
4.8.9.1. Morphine Sulfate: Tetra Bio-Pharma/Cognitive Research Corporation
4.8.9.1.1. Product Description
4.8.9.1.2. Other Development Activities
4.8.9.1.3. Clinical Development
4.8.9.1.4. Clinical Trials Information
4.8.9.1.5. Safety and Efficacy
4.8.9.1.6. Product Profile
4.8.9.2. NanaBis: Medlab Clinical/George Clinical Pty Ltd & WriteSource Medical Pty Ltd
4.8.9.3. Resiniferatoxin: Sorrento Therapeutics, Inc.
4.8.9.4. Pregabalin: Institut Cancerologie de l'Ouest/Grünenthal GmbH
Chapter 5. Competition Dashboard
5.1. Market Concentration Rate
5.2. Company Market Share Analysis (Value %), 2019
5.3. Competitor Benchmarking
Chapter 6. Global Cancer Pain Market Analysis, By Drug Type
6.1. Key Insights
6.2. Market Size and Forecast, 2017 - 2030 (Revenue - US$ Mn)
6.2.1. Opioids/Narcotics
6.2.1.1. Morphine
6.2.1.2. Fentanyl
6.2.1.3. Others
6.2.2. Non-Opioids
6.2.2.1. Acetaminophen
6.2.2.2. Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
6.2.3. Nerve Blocks
Chapter 7. Global Cancer Pain Market Analysis, By Disease Indication
7.1. Key Insights
7.2. Market Size and Forecast, 2017 - 2030 (Revenue - US$ Mn)
7.2.1. Lung Cancer
7.2.2. Colorectal Cancer
7.2.3. Breast Cancer
7.2.4. Prostate Cancer
7.2.5. Blood Cancer
7.2.6. Others
Chapter 8. Global Cancer Pain Market Analysis, By Region/Country
8.1. Key Insights
8.2. Market Size and Forecast, 2017 - 2030 (Revenue - US$ Mn)
8.2.1. North America
8.2.1.1. The U.S.
8.2.1.2. Canada
8.2.1.3. Mexico
8.2.2. Europe
8.2.2.1. The UK
8.2.2.2. Germany
8.2.2.3. France
8.2.2.4. Italy
8.2.2.5. Spain
8.2.2.6. Poland
8.2.2.7. Russia
8.2.2.8. Rest of Europe
8.2.3. Asia Pacific
8.2.3.1. China
8.2.3.2. India
8.2.3.3. Japan
8.2.3.4. Australia & New Zealand
8.2.3.5. ASEAN
8.2.3.6. Rest of Asia Pacific
8.2.4. Middle East & Africa
8.2.4.1. UAE
8.2.4.2. Saudi Arabia
8.2.4.3. South Africa
8.2.4.4. Rest of MEA
8.2.5. South America
8.2.5.1. Argentina
8.2.5.2. Brazil
8.2.5.3. Rest of South America
Chapter 9. North America Cancer Pain Market Analysis
9.1. Key Insights
9.2. Regional Market Dynamics and Impact Assessment
9.3. Market Size and Forecast, 2017 - 2030 (Revenue - US$ Mn)
9.3.1. By Drug Type
9.3.2. By Disease Indication
9.3.3. By Country
Chapter 10. Europe Cancer Pain Market Analysis
10.1. Key Insights
10.2. Regional Market Dynamics and Impact Assessment
10.3. Market Size and Forecast, 2017 - 2030 (Revenue - US$ Mn)
10.3.1. By Drug Type
10.3.2. By Disease Indication
10.3.3. By Country
Chapter 11. Asia Pacific Cancer Pain Market Analysis
11.1. Key Insights
11.2. Regional Market Dynamics and Impact Assessment
11.3. Market Size and Forecast, 2017 - 2030 (Revenue - US$ Mn)
11.3.1. By Drug Type
11.3.2. By Disease Indication
11.3.3. By Country
Chapter 12. Middle East & Africa Cancer Pain Market Analysis
12.1. Key Insights
12.2. Regional Market Dynamics and Impact Assessment
12.3. Market Size and Forecast, 2017 - 2030 (Revenue - US$ Mn)
12.3.1. By Drug Type
12.3.2. By Disease Indication
12.3.3. By Country
Chapter 13. South America Cancer Pain Market Analysis
13.1. Key Insights
13.2. Regional Market Dynamics and Impact Assessment
13.3. Market Size and Forecast, 2017 - 2030 (Revenue - US$ Mn)
13.3.1. By Drug Type
13.3.2. By Disease Indication
13.3.3. By Country
Chapter 14. The US Cancer Pain Market Analysis
14.1. Key Insights
14.2. Regional Market Dynamics and Impact Assessment
14.3. Market Size and Forecast, 2017 - 2030 (Revenue - US$ Mn)
14.3.1. By Drug Type
14.3.2. By Disease Indication
Chapter 15. The UK Cancer Pain Market Analysis
15.1. Key Insights
15.2. Regional Market Dynamics and Impact Assessment
15.3. Market Size and Forecast, 2017 - 2030 (Revenue - US$ Mn)
15.3.1. By Drug Type
15.3.2. By Disease Indication
Chapter 16. Germany Cancer Pain Market Analysis
16.1. Key Insights
16.2. Regional Market Dynamics and Impact Assessment
16.3. Market Size and Forecast, 2017 - 2030 (Revenue - US$ Mn)
16.3.1. By Drug Type
16.3.2. By Disease Indication
Chapter 17. France Cancer Pain Market Analysis
17.1. Key Insights
17.2. Regional Market Dynamics and Impact Assessment
17.3. Market Size and Forecast, 2017 - 2030 (Revenue - US$ Mn)
17.3.1. By Drug Type
17.3.2. By Disease Indication
Chapter 18. Italy Cancer Pain Market Analysis
18.1. Key Insights
18.2. Regional Market Dynamics and Impact Assessment
18.3. Market Size and Forecast, 2017 - 2030 (Revenue - US$ Mn)
18.3.1. By Drug Type
18.3.2. By Disease Indication
Chapter 19. Spain Cancer Pain Market Analysis
19.1. Key Insights
19.2. Regional Market Dynamics and Impact Assessment
19.3. Market Size and Forecast, 2017 - 2030 (Revenue - US$ Mn)
19.3.1. By Drug Type
19.3.2. By Disease Indication
Chapter 20. China Cancer Pain Market Analysis
20.1. Key Insights
20.2. Regional Market Dynamics and Impact Assessment
20.3. Market Size and Forecast, 2017 - 2030 (Revenue - US$ Mn)
20.3.1. By Drug Type
20.3.2. By Disease Indication
Chapter 21. Japan Cancer Pain Market Analysis
21.1. Key Insights
21.2. Regional Market Dynamics and Impact Assessment
21.3. Market Size and Forecast, 2017 - 2030 (Revenue - US$ Mn)
21.3.1. By Drug Type
21.3.2. By Disease Indication
Chapter 22. India Cancer Pain Market Analysis
22.1. Key Insights
22.2. Regional Market Dynamics and Impact Assessment
22.3. Market Size and Forecast, 2017 - 2030 (Revenue - US$ Mn)
22.3.1. By Drug Type
22.3.2. By Disease Indication
Chapter 23. Company Profile (Company Overview, Financial Matrix, Key Product landscape, Key Personnel, Key Competitors, Contact Address, and Business Strategy Outlook)
23.1. Aoxing Pharmaceutical Company, Inc.
23.2. BioDelivery Sciences International, Inc.
23.3. CK Life Sciences (WEX Pharmaceuticals)
23.4. Daiichi Sankyo Co., Ltd.
23.5. Hisamitsu Pharmaceutical Co., Inc.
23.6. Mundipharma International Limited
23.7. Orexo AB
23.8. Pfizer Inc.
23.9. Teva Pharmaceutical Industries Limited
23.10. Roche Holding AG
23.11. Other Prominent Players
Note: Product cover images may vary from those shown

A selection of companies mentioned in this report includes:

  • Aoxing Pharmaceutical Company, Inc.
  • BioDelivery Sciences International, Inc.
  • CK Life Sciences (WEX Pharmaceuticals)
  • Daiichi Sankyo Co., Ltd.
  • Hisamitsu Pharmaceutical Co., Inc.
  • Mundipharma International Limited
  • Orexo AB
  • Pfizer Inc.
  • Teva Pharmaceutical Industries Limited
  • Roche Holding AG
Note: Product cover images may vary from those shown